Prenatal screening has come a long way from what it used to be. Not too long ago, most expectant parents would undergo a combination of blood tests and ultrasound scans in the first trimester, receive a risk score, and then decide whether to proceed with more definitive testing. That pathway still exists, but there is now a more accurate option between the old serum markers and the more invasive procedures, and many parents are not entirely sure when it makes sense to take it or whether the cost of non-invasive prenatal testing is worth it given their specific situation.

That question is worth thinking through properly rather than treating it as a simple yes-or-no.

What Standard Screening Actually Does

The conventional approach, usually called the combined first-trimester screen or the dual/triple marker test, measures certain proteins and hormones in the mother’s blood and combines that with an ultrasound measurement called nuchal translucency. The result is a statistical risk estimate, such as 1 in 500 or 1 in 50, for conditions like Down syndrome, Edwards syndrome, and Patau syndrome. It does not tell you whether the baby has the condition. It places you in a risk category.

This matters because a lot of women who receive a “high risk” result from conventional screening go on to have completely typical pregnancies. And on the other side, some low-risk results do not catch everything either. The sensitivity of standard serum screening for Down syndrome is around 80 to 90 per cent, depending on the method used, which means there is room for both false positives and false negatives. When a result comes back as high risk, the typical next step used to be amniocentesis or CVS, both of which carry a small but real risk of miscarriage.

Where NIPT Fits In and What the Cost Question Really Means

Non-invasive prenatal testing works differently. It analyses fragments of fetal DNA circulating in the mother’s bloodstream and can detect chromosomal abnormalities with significantly higher accuracy than serum-based methods, achieving sensitivity and specificity above 99 per cent for the common trisomies. It is a blood draw, not a procedure, which means there is no risk to the pregnancy itself.

The prenatal screening decision often comes down to a cost-benefit analysis with two sides. On one hand, NIPT does cost more than a standard serum screen. On the other hand, for women who receive a high-risk standard result, the realistic alternative is an invasive diagnostic test that carries procedural risks. When you frame it that way, the cost calculus changes. A study by MedGenome involving over 500 samples found that close to 97 per cent of women who were classified as intermediate to high risk by conventional screening turned out to be low risk on NIPT, which meant they were able to avoid amniocentesis entirely. That is not a small thing.

The cost of NIPT is not just the test fee, and neither is the cost of skipping it. The downstream decisions, the anxiety of waiting after an invasive procedure, the small but non-zero procedural risk — those are real factors in the calculation. MedGenome’s Claria NIPT, which is validated on an Indian population cohort and processed in a CAP and NABL-accredited lab in India, delivers results within seven working days and includes access to genetic counselling as part of the process.

Who Benefits Most from Choosing NIPT

There are some situations where NIPT is especially worth considering. Women over 35 are the classic high-risk group because the statistical probability of chromosomal conditions rises with maternal age, and the standard screens become less reliable as a standalone tool. Women who have received an abnormal ultrasound finding or who have a family history of chromosomal disorders are also in a category where the additional accuracy of NIPT changes what you actually know at the end of the test.

Twin pregnancies add complexity, and standard serum markers become harder to interpret in that context. There is a dedicated NIPT panel for twins that addresses this. Women who have experienced recurrent miscarriages are another group for whom having more reliable early information can be genuinely useful rather than just reassuring.

A lot of women who do not fall into any clear “high risk” category still choose NIPT because they want a more precise answer from the start rather than working through a two-step process. That is a completely reasonable position to take, and guidelines from several medical bodies now support offering NIPT to all pregnant women, not just those with identifiable risk factors.

The question of when NIPT makes sense over standard screening is, at its most practical level, a question about how much certainty you need and what you would do with that information. Looking at the accuracy gap between the two approaches, and thinking about what a high-risk result on standard screening would actually lead to, tends to make the comparison clearer before the appointment.